title: The use of animal models in multiple myeloma.
abstract: In myeloma, the understanding of the tissular, cellular and molecular mechanisms of the interactions between tumor plasma cells and bone cells have progressed from in vitro and in vivo studies. However none of the known animal models of myeloma reproduce exactly the human form of the disease. There are currently three types of animal models: (1) injection of pristane oil in BALB/c mice leads to intraperitoneal plasmacytomas but without bone marrow colonization and osteolysis; (2) injection of malignant plasma cell lines in immunodeficient mice SCID or NOD/SCID; the use of the SCID-hu or SCID-rab model allows the use of fresh plasma cells obtained from MM patients; (3) injection of allogeneic malignant plasma cells (5T2MM, 5T33) in the C57BL/KalwRij mouse induces bone marrow proliferation and osteolytic lesions. These cells did not grow in vitro and can be propagated by injection of plasma cells isolated from bone marrow of a mouse at end stage of the disease into young recipient mice. The 5TGM1 is a subclone of 5T33MM cells and can grow in vitro. Among the different models, the 5TMM models and SCID-hu/SCID-rab models were extensively used to test pathophysiological hypotheses and to assess anti-osteoclastic, anti-osteoblastic or anti-tumor therapies in myeloma. In the present review, we report the different types of animal models of MM and describe their interests and limitations.
authors.affiliation: GEROM groupe études remodelage osseux et biomatériaux-LHEA, IRIS-IBS institut de biologie en santé, LUNAM université, CHU d'Angers, 49933 Angers cedex, France. Electronic address: helene.libouban@univ-angers.fr.
authors.forename: H
authors.initials: H
authors.lastname: Libouban
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016025:Bone Transplantation; D002999:Clone Cells / Q000637:transplantation; D016332:Fetal Tissue Transplantation; D064593:Heterografts; D006801:Humans; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D023421:Models, Animal; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D009363:Neoplasm Proteins / Q000502:physiology; D009368:Neoplasm Transplantation; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology; D010950:Plasma Cells / Q000637:transplantation; D010954:Plasmacytoma / Q000139:chemically induced; D011817:Rabbits; D013729:Terpenes / Q000008:administration & dosage / Q000633:toxicity; D059016:Tumor Microenvironment
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D013729:Terpenes; C009042:pristane
keywords: 5T2MM; 5T33MM; 5TGM1; BALB/c; C57BL/KalwRij; Modèle murin de myélome; Murine model of myeloma; Osteolysis; Ostéolyse; Pristane; SCID; SCID-hu; Xenograft; Xénogreffe